Chemplast Sanmar Ltd: From PVC Dreams to Margin Nightmares ☠️☕
1. At a Glance
Chemplast Sanmar—India’s “polymer prince turned debt donkey”—sells PVC, specialty chemicals, caustic soda, and hydrogen peroxide, but lately its financials look like expired lab reagents. Q1 FY26 saw sales at ₹1,100 Cr (down ~4% YoY) and net loss ballooning to ₹64 Cr. Margins? Barely 2%. For a company that once bragged about being South India’s PVC king, today it looks more like a struggling extra in a Tata Chemicals–SRF blockbuster.
2. Introduction
Once a big fish in specialty PVC and custom chemical manufacturing, Chemplast Sanmar has ended up like a lab rat stuck in its own experiment. With a ₹6,643 Cr market cap and plants across Tamil Nadu and Puducherry, the company boasts a fully backward-integrated supply chain—from chlorine to vinyl chloride. On paper, it’s perfect. In reality, global dumping of PVC and collapsing caustic soda prices have turned its P&L into horror literature.
Margins dropped from 9% in FY23 to 1% in FY24, barely recovering to 5% in FY25. Now Q1 FY26 margins are back to an anaemic 2%. That’s like studying hard, scoring 10/100, then boasting about improvement because you managed 20/100. Investors have been more patient than a pharma trial subject, but the question remains—how long can one wait for the “specialty turnaround” story?
Stick around—things get spicier two scrolls down.
3. Business Model – WTF Do They Even Do?
Chemplast has three science projects running simultaneously:
Suspension PVC (55% revenue Q1 FY26): Pipes, profiles, roofing sheets, hoses—you name it. South India’s second-largest PVC producer. Trouble is, Chinese dumping has made domestic players look like shopkeepers in Chandni Chowk—no pricing power.
Specialty Chemicals (32% revenue): Paste PVC resin (used in footwear, upholstery, artificial leather) and custom manufacturing for global agrochem and pharma giants. They own 66% market share in paste PVC. Sounds sexy, but margins don’t show it yet.
Value-added Chemicals (13% revenue): Hydrogen peroxide, caustic soda, chloromethanes—industrials love these, but prices collapsed faster than FTX tokens.
On paper, this diversification looks solid. But when every segment faces pricing pressure, you get Chemplast’s FY26 story: Jack of all trades, master of none, margin of nothing.
4. Financials Overview
Source table
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue (₹ Cr)
1,100
1,145
1,151
-3.9%
-4.4%
EBITDA (₹ Cr)
17
124
37
-86.3%
-54.0%
PAT (₹ Cr)
-64.2
24
-54
-369%
-18.9%
EPS (₹)
-4.06
1.51
-3.43
N/A
N/A
Commentary: Sales have stagnated, EBITDA collapsed 86%, and PAT looks like a sinking ship. EPS is firmly in negative territory. Basically, every quarter the “PVC prince” is burning shareholder wealth like lab ethanol.
EV/EBITDA: EV = ₹7,761 Cr. FY25 EBITDA = ₹112 Cr → EV/EBITDA = ~69x. That’s startup valuation levels for a legacy chemical player. Fair value range should be 12–18x EBITDA → ₹1,300–₹2,000 Cr EV, or ₹70–₹120/share.
DCF: Even with generous 12% WACC and 10–12% growth assumption, DCF throws up a fair value of ₹100–₹150/share.
